Epoch Investment Partners Inc. Decreases Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Epoch Investment Partners Inc. reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 23.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 448,037 shares of the medical research company’s stock after selling 141,033 shares during the period. Epoch Investment Partners Inc.’s holdings in Edwards Lifesciences were worth $42,814,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. DSM Capital Partners LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth $28,000. Crewe Advisors LLC acquired a new position in shares of Edwards Lifesciences during the first quarter worth $28,000. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth $34,000. Riverview Trust Co acquired a new position in shares of Edwards Lifesciences during the first quarter worth $34,000. Finally, Pingora Partners LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth $38,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total value of $1,212,624.00. Following the completion of the transaction, the vice president now owns 173,849 shares in the company, valued at approximately $14,639,824.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the completion of the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at $14,639,824.29. The disclosure for this sale can be found here. Insiders sold 81,099 shares of company stock worth $7,003,553 in the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded up $2.67 during trading on Friday, hitting $62.37. 14,111,391 shares of the stock were exchanged, compared to its average volume of 5,310,790. The stock’s fifty day moving average is $87.98 and its 200 day moving average is $86.92. The stock has a market cap of $37.58 billion, a PE ratio of 26.88, a P/E/G ratio of 2.31 and a beta of 1.11. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.71. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. The firm had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. Edwards Lifesciences’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.66 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.71 EPS for the current year.

Wall Street Analysts Forecast Growth

EW has been the topic of several recent analyst reports. Wells Fargo & Company cut their price target on shares of Edwards Lifesciences from $99.00 to $90.00 and set an “overweight” rating on the stock in a report on Thursday. Robert W. Baird cut shares of Edwards Lifesciences from an “outperform” rating to a “neutral” rating and cut their price target for the company from $102.00 to $70.00 in a report on Thursday. Oppenheimer cut their price target on shares of Edwards Lifesciences from $100.00 to $90.00 and set an “outperform” rating on the stock in a report on Thursday. Piper Sandler cut their price target on shares of Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating on the stock in a report on Thursday. Finally, Bank of America cut shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and cut their price target for the company from $105.00 to $75.00 in a report on Thursday. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $82.10.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.